期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

拉米夫定抗乙型肝炎病毒治疗的耐药问题 被引量：3

下载PDF
导出
摘要 拉米夫定耐乙型肝炎病毒(HBV)治疗中出现的耐药性与病毒基因变异有关,最常见于YMDD区域变异;拉米夫定耐药性可能诱发病情恶化并伴随HBeAg血清学转换;病毒变异发生率随疗程延长而增加,可能与治疗前HBV DNA及谷丙转氨酶水平有关;合理的联合或序贯抗HBV治疗是减少病毒耐药性的可行策略,村于已发生耐药性病人应考虑有效替换治疗、联合治疗或继续拉米夫定治疗,并监测病情发展。
作者 陈永鹏
机构地区 第一军医大学南方医院感染内科
出处 《国外医学（内科学分册）》 2002年第1期19-21,25,共4页 Foreign Medical Sciences(Section of Internal Medicine)
关键词 乙型肝炎病毒 基因变异 拉米夫定 抗药性 治疗
分类号 R512.62 [医药卫生—内科学] R978.7 [医药卫生—药品]
  • 相关文献

参考文献28

  • 1Lee WM. [J]. N Engl J Med, 1997,337(24): 1733-1745.
  • 2Josefson D. [J]. BMJ, 1998,317:1034.
  • 3Allen MI, Deslauriers M, Andrews CW, et al. [J].Hepatology, 1998,27:1670-1677.
  • 4Honkoop P,Niesters HGM,de Man RAM,et al. [J]. J Hepatol, 1997,26: 1393-1395.
  • 5Niesters HG, Honkoop P, Haagsma EB, et al. [J]. J Infect Dis, 1998, 177:1382-1385.
  • 6Atkins M,Hunt CM,Brown N,et al. [A]. Hepatology,1998,28(Suppl 1) :319A.
  • 7Fu L. Cheng YC.[J].Biochem Pharmacol,1998,55:1567-1572.
  • 8Ono-Nita SK,Kato N,Shiratori Y,et al. [J]. Hepatology, 1999.29(3) :939-945.
  • 9Yeh CT, Chien RN, Chu CM, et al. [J]. Hepatology,2000,31:1318-1326.
  • 10Lai CL, Chien RN,Leung NWY,et al. [J]. N Engl J Med, 1998,339: 61-68.

同被引文献39

  • 1Liotta DC, Schinazi RF, Choi WB. Method for the synthesis,compositions and use of 2'-deoxy-5-fluoro-3'-thiacytidine and related compoungs[ P]. USP,5,700,937,1997 - 12 - 08.
  • 2Nair V, Jahnke TS. Antiviral activities of isomeric dideoxynucleosies of D-and L-Related steteochemistry [ J ]. Antimicrob Agents Chemother, 1995,39(5) : 1017 - 1029.
  • 3Wang P, Hong JH, Cooperwood JS, et al. Recent advance in L-nucleosides: chemisrty and biology [J]. Antiviral Res, 1998, 40(1-2):19-44.
  • 4Glumina G, Song GY, Chu CK. L-nucleosides as chemotherapeutic agents[J]. FEMS Microbiol Lett ,2001,202(1) :9- 15.
  • 5Murakami E, Ray AS, Schinazi RF, et al. Investigating the effects of stereochemistry on incorporation and removal of 5-fluorocytidine analogs by mitochondrial DNA polymerase gamma:comparison of D-and L-D4FC-TP[J]. Antiviral Res ,2004,62(1) :57 - 64.
  • 6Sorbera LA, Castaner J, Bayes M. ACH-126443 [J]. Drug Fut,2002,27(12) : 1131 - 1140.
  • 7Ray AS, Murakami E, Peterson CN, et al. Interactions of enantiomers of 2', 3'-didehydro-2', 3'-dideoxy-fluorocytidine with wild type and M184V mutant HIV-1 reverse transcriptase [J].Antiviral Res ,2002,56(3) : 189 - 205.
  • 8Durschman GE, Bridges EG, Liu SH, et al. Metabolism of 2', 3'-dideoxy-2',3'- didehydro-L-(-)-5-fluomcytidine and its activity in combination with clinically approved anti-human immunodeficiency virus D-( + ) nucleoside analoge in vitro [ J]. Antimicrobial Agents & Chemother, 1998,42(7) : 1799 - 1804.
  • 9Lin TS, Luo MZ, Liu MC, et al. Design and synthesis of 2', 3'-dideoxy-2', 3'-didehydro-beta-L-cytidine ( bet-L-d4C ) and 2', 3'-dideoxy-2', 3'-didehydro-beta-L-fuorocytidine ( beta-L-Fd4C ), two exceptionally potent inhibitors of human hepatitis B virus(HBV) and potent inhibitors of human immuno deficiency virus (HIV) in vitro[J]. J Med Chem, 1996,39(9) : 1757 - 1759.
  • 10Zhu YL, Dutschman GE, Liu SW, et al. Anti-hepatitis B viral activity and metabolism of 2', 3'- dideoxy-2', 3'- didehydro- beta- L-5-fluorocytidine [ J ]. Antimicrob Agents & Chemother, 1998,42 ( 7 ) :1805 - 1810.

引证文献3

二级引证文献8

国外医学（内科学分册）
2002年 第1期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部